My watch list  

46 Current news of CureVac


You can refine your search further. Select from the filter options on the left to narrow down your results.

image description
Personalized cancer vaccines: CureVac acquires oncology startup

CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform


CureVac N.V. announced its acquisition of Frame Cancer Therapeutics, a private company focused on advanced genomics and bioinformatics to identify both unique and shared neoantigens across different cancer types. “The addition of Frame’s technology and talent to CureVac’s oncology research ...


image description
CureVac and GSK Enter into Pandemic Preparedness Contract with German Government

Five-year contract enables production of up to 80 million vaccine doses at short notice in case of a public health emergency


CureVac N.V. and GSK announced that they have entered into a contract with the German federal government to supply mRNA vaccines within a broader tender for pandemic preparedness in Germany. Following a setup period of a maximum of two years, the contract grants the German federal government ...


image description
CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate


CureVac N.V. announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK. The clinical trial is expected to provide valuable data to further evaluate the performance of CureVac’s ...


image description
CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer

The RNA Printer is CureVac’s integrated and automated manufacturing solution for RNA vaccines and therapeutics


CureVac N.V. announced that it has established CureVac RNA Printer GmbH, a fully-owned CureVac company to advance The RNA Printer®. The RNA Printer® is CureVac’s solution for integrated and automated manufacturing of GMP-grade RNA vaccines and therapeutics. The new entity is designed as a ...


image description
CureVac starts Phase 1 Study with Multivalent Influenza Vaccine Candidate

Developed in Collaboration with GSK


CureVac N.V. announced that it has dosed the first participant in a Phase 1 study of its seasonal influenza second-generation mRNA vaccine candidate, CVSQIV, developed in collaboration with GSK. The differentiated multivalent vaccine candidate features multiple non-chemically modified mRNA ...


image description
CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry

Dr. Mariola Fotin-Mleczek will resign from CureVac


CureVac N.V. announced that the company’s Chief Technology Officer, Dr. Mariola Fotin-Mleczek, will resign from CureVac effective January 31, 2022. Mariola exits her role at CureVac after nearly 16 years of scientific leadership at the company, and 33 years in Germany, with plans to pursue a ...


image description
CureVac Streamlines European Network for mRNA Product Manufacturing

Contracts with manufacturing partners WACKER and Celonic terminated


CureVac N.V. announced its strategic decision to adjust the long-term footprint of the external European manufacturing network for its mRNA product pipeline. The decision was made in response to the reduced short-term peak demand for vaccines following the first wave of the pandemic vaccination ...


image description
CureVac’s Second-Generation Vaccine Candidate Demonstrates Improved Immune Response and Protection

The optimized mRNA backbone has the potential for a multivalent or combination approach to address multiple emerging variants in one vaccine


CureVac N.V. and GSK announced the publication of preclinical data investigating immune responses as well as the protective efficacy of CureVac’s first-generation vaccine candidate, CVnCoV, and second-generation vaccine candidate, CV2CoV, against SARS-CoV-2 challenge in non-human primates. The ...


image description
CureVac’s First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation


CureVac N.V. announced that the independent Data Safety Monitoring Board (DSMB) has confirmed that the pivotal Phase 2b/3 study (HERALD) for CureVac’s first-generation COVID-19 vaccine candidate, CVnCoV, has passed a first interim analysis at 59 adjudicated COVID-19 cases. The DSMB confirmed that ...


image description
Second-Generation COVID-19 Vaccine Candidate Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study

Fast onset of strong neutralizing antibody titers after first vaccination


CureVac N.V. announced together with its collaboration partner GSK, first preclinical data in a rat model, showing that its second-generation COVID-19 vaccine candidate, CV2CoV, induces high levels of antigen production as well as strong and dose-dependent immune responses in vaccinated animals. ...


Page 1 From 5
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE